Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: A 10-week open-label study

Chad A. Bousman, Daniel J. Müller, Chee H. Ng, Keith Byron, Michael Berk, Ajeet B. Singh

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)


Background Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice. However, the clinical validity of these tools has not been adequately tested, particularly for specific antidepressants. Objective To examine the concordance between the actual dose and a polygene pharmacogenetic predicted dose of desvenlafaxine needed to achieve symptom remission. Materials and methods A 10-week, open-label, prospective trial of desvenlafaxine among Caucasian adults with major depressive disorder (n=119) was conducted. Dose was clinically adjusted and at the completion of the trial, the clinical dose needed to achieve remission was compared with the predicted dose needed to achieve remission. Results Among remitters (n=95), there was a strong concordance (Kendall's τ-b=0.84, P=0.0001; Cohen's κ=0.82, P=0.0001) between the actual and the predicted dose need to achieve symptom remission, showing high sensitivity (≥85%), specificity (≥86%), and accuracy (≥89%) of the tool. Conclusion Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalPharmacogenetics and Genomics
Issue number1
Publication statusPublished - Jan 2017
Externally publishedYes


  • Antidepressants
  • Desvenlafaxine
  • Major depression
  • Personalized medicine
  • Pharmacogenetics
  • Pharmacogenomics
  • Precision medicine

Cite this